osis and treatment of infectious pathogens. AdvanDx's
products and services enable dramatic improvements in patient care and
outcomes while reducing hospital costs.
Every year, 350,000 patients contract bloodstream infections, causing
over 90,000 unnecessary deaths and significant costs to the healthcare
system. The rapid identification of infecting pathogens is crucial to
ensure early and appropriate therapy to save lives and reduce patient
length-of-stay. In response, AdvanDx leverages its molecular diagnostic
products to detect and identify infectious pathogens and provide
therapy-directing results in hours versus days.
AdvanDx's easy-to-use products employ standard lab techniques and
equipment to reduce startup, implementation, technician and maintenance
time, while providing fast results without sacrificing accuracy. Major
medical centers, reference labs, government institutions and community
hospitals throughout the United States, Europe and Asia rely on AdvanDx
products, supported by a global network of service partners.
For more information visit http://www.AdvanDx.com
'/>"/>SOURCE AdvanDx Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 Related biology technology :1.
Acrongenomics on Track to Acquire Molecular Vision2.
Vermillion and Johns Hopkins Sign Collaborative Research and License Agreements to Develop Molecular Diagnostic Tests3.
Acrongenomics Acquires Equity Stake in Molecular Vision4.
Amsterdam Molecular Therapeutics to Appoint Philippe van Holle (Celgene) to Supervisory Board5.
The Dark Report and Siemens Introduce the Worlds First Integrated Molecular Summit6.
The Center for Molecular Medicine Doubles Lab Staff, Expands Lab Space by 100 Percent7.
Peakdale Molecular Announces GBP 1 Million Funding to Support Expansion and Growth8.
Center for Molecular Medicine Selected to Provide DNA Analysis for Childrens Oncology Group Leukemia Study9.
UC Berkeley Expands Molecular Toxicology Curriculum to Include GeneGos Platform10.
Seahorse Bioscience Appoints Former Molecular Devices Executive Dr. Joseph D. Keegan to Board of Directors11.
Center for Molecular Medicine Among First Labs in Nation to Offer Groundbreaking Test to Aid in Treatment of Colorectal Cancer